Versant Venture Capital VI, L.P.

CIK: 0001687880

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)49 (83.1%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)0 (0.0%)

Compensation grants

Other (G, F, J, C, D, …)10 (16.9%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (3)

LENZ

LENZ Therapeutics, Inc.

10% Owner

LVTX

LAVA Therapeutics NV

10% Owner

GLUE

Monte Rosa Therapeutics, Inc.

10% Owner

Discretionary Trading P&L

Holdings

Transaction History (59 total)

LENZ
LENZ Therapeutics, Inc.
Sep 30, 2025
Sale(S)
Indirect
123 shares at avg. $47.01$6K
LENZ
LENZ Therapeutics, Inc.
Sep 30, 2025
Sale(S)
Indirect
57.5K shares at avg. $46.41$2.7M
LENZ
LENZ Therapeutics, Inc.
Sep 30, 2025
Sale(S)
Direct
177 shares at avg. $47.01$8K
LENZ
LENZ Therapeutics, Inc.
Sep 30, 2025
Sale(S)
Direct
49.7K shares at avg. $45.35$2.3M
LENZ
LENZ Therapeutics, Inc.
Sep 30, 2025
Sale(S)
Direct
83.1K shares at avg. $46.41$3.9M
LENZ
LENZ Therapeutics, Inc.
Sep 30, 2025
Sale(S)
Indirect
34.4K shares at avg. $45.35$1.6M
LVTX
LAVA Therapeutics NV
Sep 19, 2025
Sale(S)
Indirect
532.9K shares at avg. $1.40$747K
LVTX
LAVA Therapeutics NV
Sep 19, 2025
Sale(S)
Direct
2.4M shares at avg. $1.40$3.3M
LENZ
LENZ Therapeutics, Inc.
Sep 18, 2025
Sale(S)
Direct
49.5K shares at avg. $41.59$2.1M
LENZ
LENZ Therapeutics, Inc.
Sep 18, 2025
Sale(S)
Direct
268 shares at avg. $43.30$12K
LENZ
LENZ Therapeutics, Inc.
Sep 18, 2025
Sale(S)
Indirect
20.1K shares at avg. $43.00$866K
LENZ
LENZ Therapeutics, Inc.
Sep 18, 2025
Sale(S)
Indirect
132 shares at avg. $43.30$6K
LENZ
LENZ Therapeutics, Inc.
Sep 18, 2025
Sale(S)
Indirect
24.4K shares at avg. $41.59$1.0M
LENZ
LENZ Therapeutics, Inc.
Sep 18, 2025
Sale(S)
Direct
40.9K shares at avg. $43.00$1.8M
LVTX
LAVA Therapeutics NV
Sep 18, 2025
Sale(S)
Indirect
228.8K shares at avg. $1.44$330K
LVTX
LAVA Therapeutics NV
Sep 18, 2025
Sale(S)
Direct
366.1K shares at avg. $1.44$528K
LVTX
LAVA Therapeutics NV
Sep 17, 2025
Sale(S)
Direct
362.8K shares at avg. $1.49$540K
LVTX
LAVA Therapeutics NV
Sep 17, 2025
Sale(S)
Indirect
226.7K shares at avg. $1.49$338K
LVTX
LAVA Therapeutics NV
Sep 16, 2025
Sale(S)
Indirect
192.3K shares at avg. $1.53$295K
LVTX
LAVA Therapeutics NV
Sep 16, 2025
Sale(S)
Direct
307.7K shares at avg. $1.53$472K
LENZ
LENZ Therapeutics, Inc.
Aug 26, 2025
Sale(S)
Direct
44K shares at avg. $38.97$1.7M
LENZ
LENZ Therapeutics, Inc.
Aug 26, 2025
Sale(S)
Indirect
21.7K shares at avg. $38.97$844K
LENZ
LENZ Therapeutics, Inc.
Aug 26, 2025
Sale(S)
Direct
3.5K shares at avg. $39.50$137K
LENZ
LENZ Therapeutics, Inc.
Aug 26, 2025
Sale(S)
Indirect
1.7K shares at avg. $39.50$67K
LENZ
LENZ Therapeutics, Inc.
Aug 25, 2025
Sale(S)
Direct
50.3K shares at avg. $39.53$2.0M

		Type	Shares	Price		Ownership
Sep 30, 2025	LENZ LENZ Therapeutics, Inc.	Sale(S)	123	$47.01	$5,783	Indirect
Sep 30, 2025	LENZ LENZ Therapeutics, Inc.	Sale(S)	57,502	$46.41	$2,668,484	Indirect
Sep 30, 2025	LENZ LENZ Therapeutics, Inc.	Sale(S)	177	$47.01	$8,321	Direct
Sep 30, 2025	LENZ LENZ Therapeutics, Inc.	Sale(S)	49,701	$45.35	$2,254,174	Direct
Sep 30, 2025	LENZ LENZ Therapeutics, Inc.	Sale(S)	83,066	$46.41	$3,854,827	Direct
Sep 30, 2025	LENZ LENZ Therapeutics, Inc.	Sale(S)	34,405	$45.35	$1,560,428	Indirect
Sep 19, 2025	LVTX LAVA Therapeutics NV	Sale(S)	532,870	$1.40	$746,764	Indirect
Sep 19, 2025	LVTX LAVA Therapeutics NV	Sale(S)	2,370,533	$1.40	$3,322,065	Direct
Sep 18, 2025	LENZ LENZ Therapeutics, Inc.	Sale(S)	49,479	$41.59	$2,057,871	Direct
Sep 18, 2025	LENZ LENZ Therapeutics, Inc.	Sale(S)	268	$43.30	$11,604	Direct
Sep 18, 2025	LENZ LENZ Therapeutics, Inc.	Sale(S)	20,148	$43.00	$866,441	Indirect
Sep 18, 2025	LENZ LENZ Therapeutics, Inc.	Sale(S)	132	$43.30	$5,716	Indirect
Sep 18, 2025	LENZ LENZ Therapeutics, Inc.	Sale(S)	24,370	$41.59	$1,013,568	Indirect
Sep 18, 2025	LENZ LENZ Therapeutics, Inc.	Sale(S)	40,907	$43.00	$1,759,156	Direct
Sep 18, 2025	LVTX LAVA Therapeutics NV	Sale(S)	228,791	$1.44	$329,871	Indirect
Sep 18, 2025	LVTX LAVA Therapeutics NV	Sale(S)	366,111	$1.44	$527,859	Direct
Sep 17, 2025	LVTX LAVA Therapeutics NV	Sale(S)	362,806	$1.49	$540,291	Direct
Sep 17, 2025	LVTX LAVA Therapeutics NV	Sale(S)	226,726	$1.49	$337,640	Indirect
Sep 16, 2025	LVTX LAVA Therapeutics NV	Sale(S)	192,293	$1.53	$294,824	Indirect
Sep 16, 2025	LVTX LAVA Therapeutics NV	Sale(S)	307,707	$1.53	$471,776	Direct
Aug 26, 2025	LENZ LENZ Therapeutics, Inc.	Sale(S)	43,978	$38.97	$1,714,016	Direct
Aug 26, 2025	LENZ LENZ Therapeutics, Inc.	Sale(S)	21,661	$38.97	$844,224	Indirect
Aug 26, 2025	LENZ LENZ Therapeutics, Inc.	Sale(S)	3,465	$39.50	$136,875	Direct
Aug 26, 2025	LENZ LENZ Therapeutics, Inc.	Sale(S)	1,707	$39.50	$67,430	Indirect
Aug 25, 2025	LENZ LENZ Therapeutics, Inc.	Sale(S)	50,270	$39.53	$1,986,947	Direct

1-25 of 59 transactions

About Versant Venture Capital VI, L.P.

Versant Venture Capital VI, L.P. (SEC CIK 0001687880) files insider reports with the SEC as 10% Owner of LENZ Therapeutics, Inc. (LENZ), 10% Owner of LAVA Therapeutics NV (LVTX) and 10% Owner of Monte Rosa Therapeutics, Inc. (GLUE).

Signal8 holds 14 ownership filings by Versant Venture Capital VI, L.P. (1 Form 3, 13 Form 4), filed between Sep 13, 2024 and Oct 2, 2025. Those filings report 59 transactions, from Sep 11, 2024 to Sep 30, 2025. Signal8's Form 4 history starts in Sep 2024.

The business address on Versant Venture Capital VI, L.P.'s filings is in SAN FRANCISCO, CA.

Recent filings by Versant Venture Capital VI, L.P.

Sep 30, 2025: Open-market sales of LENZ shares (6 lines, Form 4, code S).
Sep 19, 2025: Open-market sales of LVTX shares (2 lines, Form 4, code S).
Sep 18, 2025: Open-market sales of LENZ shares (6 lines, Form 4, code S).
Sep 18, 2025: Open-market sales of LVTX shares (2 lines, Form 4, code S).
Sep 17, 2025: Open-market sales of LVTX shares (2 lines, Form 4, code S).

Other insiders filing for LENZ Therapeutics, Inc. (LENZ)

Chevallard Daniel R., Chief Financial Officer
RA CAPITAL MANAGEMENT, L.P., 10% Owner
George Jeffrey P., Director
Drapkin Kimberlee C, Director
MCCOLLUM JAMES W, Director
Thunen Shelley B, Director

How to read Form 4 transaction codes